Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 3, 2012, Pages 221-227

  Chou, Chien Hsuan ^a   Lee, Nan Yao ^a   Lee, Hsin Chun ^a,b   Chang, Chia Ming ^a   Lee, Ching Chi ^a   Ko, Wen Chien ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Bacteremia; Daptomycin; Linezolid; Vancomycin resistant Enterococcus

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; DAPTOMYCIN; GENTAMICIN; LINEZOLID; STREPTOMYCIN; TEICOPLANIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; CLINICAL FEATURE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS GALLINARUM; FEMALE; HOSPITALIZATION; HUMAN; IN VITRO STUDY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY; SHOCK; TAIWAN; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OXAZOLIDINONES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84861234052     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.11.005     Document Type: Article

References (32)

1. Pfaller M.A., Jones R.N., Doern G.V., Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998, 42:1762-1770.
2. Low D.E., Keller N., Barth A., Jones R.N. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001, 32:S133-S145.
3. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32:470-485. National Nosocomial Infections Surveillance System.
4. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance stud. Clin Infect Dis 2004, 39:309-317.
5. Chang C.M., Wang L.R., Lee H.C., Lee N.Y., Wu C.J., Ko W.C. Characterisation of vancomycin-resistant enterococci from hospitalised patients at a tertiary centre over a seven-year period. J Hosp Infect 2010, 74:377-384.
6. Diaz Granados C.A., Zimmer S.M., Klein M., Jernigan J.A. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005, 41:327-333.
7. Salgado C.D., Farr B.M. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003, 24:690-698.
8. Murray B.E. Vancomycin-resistant enterococcal infections. N Engl J Med 2000, 342:710-721.
9. Losonsky G.A., Wolf A., Schwalbe R.S., Nataro J., Gibson C.B., Lewis E.W. Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents. Clin Infect Dis 1994, 19:163-165.
10. Hayden M.K., Trenholme G.M., Schultz J.E., Sahm D.F. In vitro development of teicoplanin resistance in a VanB Enterococcus faecalis isolate. J Infect Dis 1993, 167:1224-1227.
11. Arias C.A., Murray B.E. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008, 6:637-655.
12. Herrero I.A., Issa N.C., Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002, 346:867-869.
13. Ruggero K.A., Schroeder L.K., Schreckenberger P.C., Mankin A.S., Quinn J.P. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 2003, 47:511-513.
14. Pfaller M.A., Sader H.S., Jones R.N. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007, 57:459-465.
15. Anastasiou D.M., Thorne G.M., Luperchio S.A., Alder J.D. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006, 28:385-388.
16. Cubicin [package insert] 2007, Cubist Pharmaceuticals, Inc., Lexington, MA.
17. Segreti J.A., Crank C.W., Finney M.S. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006, 26:347-352.
18. Kvirikadze N., Suseno M., Vescio T., Kaminer L., Singh K. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis 2006, 38:290-292.
19. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
20. Fagon J.Y., Chastre J., Novara A., Medioni P., Gibert C. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med 1993, 19:137-144.
21. Sader H.S., Jones R.N. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin surveillance program (2007-2008). Diagn Microbiol Infect Dis 2009, 65:158-162.
22. Performance standards for antimicrobial susceptibility testing 2007, Clinical Laboratory Standard Institute (CLSI), CLSI, Wayne, Pa, Document M100-S15.
23. European Committee on Antimicrobial Susceptibility Testing. (EUCAST) Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, January 2011. Available from: . [accessed 27.04.11]. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf.
24. Chou Y.Y., Lin T.Y., Lin J.C., Wang N.C., Peng M.Y., Chang F.Y. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis. J Microbiol Immunol Infect 2008, 41:124-129.
25. Mave V., Garcia-Diaz J., Islam T., Hasbun R. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?. J Antimicrob Chemother 2009, 64:175-180.
26. Crank C.W., Scheetz M.H., Brielmaier B., Rose W.E., Patel G.P., Ritchie D.J., et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clin Ther 2010, 32:1713-1719.
27. McKinnell J.A., Patel M., Shirley R.M., Kunz D.F., Moser S.A., Baddley J.W. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect 2010, 15:1-9.
28. Gallagher J.C., Perez M.E., Marino E.A., LoCastro L.G., Abrardo L.A., MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009, 29:792-799.
29. Erlandson K.M., Sun J., Iwen P.C., Rupp M.E. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008, 46:30-36.
30. Garbutt J.M., Ventrapragada M., Littenberg B., Mundy L.M. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis 2000, 30:466-472.
31. Lodise T.P., McKinnon P.S., Tam V.H., Rybak M.J. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 2002, 34:922-929.
32. Ghanem G., Hachem R., Jiang Y., Chemaly R.F., Raad I. Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol 2007, 28:1054-1059.